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Background/aim: Genetic predisposition is implicated in the etiology of metabolic syndrome. This study aimed to investigate
the association of vaspin rs2236242 and leptin rs7799039 polymorphisms with their serum levels and with the risk of developing
metabolic syndrome in Egyptian women.
Materials and methods: This case control study included 100 Egyptian women with metabolic syndrome and 100 without metabolic
syndrome. The genotypes of vaspin rs2236242 and leptin rs7799039 were detected by a methodology based on PCR-RFLP. Serum vaspin
and leptin levels were determined by ELISA.
Results: The metabolic syndrome group was associated with higher serum vaspin and leptin levels when compared to the nonmetabolic
syndrome group. The AA genotype of leptin rs7799039 was associated with metabolic syndrome and with higher serum leptin levels,
while the different genotypes of vaspin rs2236242 were not associated with metabolic syndrome or different serum vaspin levels.
Conclusion: The AA genotype of leptin rs7799039 was associated with metabolic syndrome and higher serum leptin levels. Serum
leptin and vaspin can be used as diagnostic markers of metabolic syndrome.
Key words: Gene polymorphism, leptin rs7799039, metabolic syndrome, vaspin rs2236242

1. Introduction
Metabolic syndrome (MeS) became a major health
problem after the worldwide prevalence of obesity,
primarily central obesity (1). This is because it enhances
the possibility of developing cardiovascular diseases and
type 2 diabetes (2). The central adipose tissues secrete a
large number of adipokines, which is considered a major
factor in disease development (3).
Vaspin, first identified by Hida et al. (4) in a rat model of
type 2 diabetes, is a serine protease inhibitor derived from
visceral adipose tissue. The vaspin level correlates with
the body mass index (BMI), as its expression is specific
to adipocytes in visceral adipose tissues. Vaspin improves
glucose tolerance and has insulin-sensitizing effects on
adipocyte (5). This may be due to its antiinflammatory
effect (6) or inhibition of proteases that degrade
antihyperglycemic and antiorexigenic molecules (7). A
single nucleotide polymorphism in intron 4 of a vaspin
* Correspondence: drhodagad@yahoo.com

gene (its approved code by the HUGO Gene Nomenclature
Committee is SERPINA12), vaspin rs2236242, was found
to be strongly associated with diabetes (8).
Leptin, the other adipokine, is almost exclusively
expressed by differentiated adipocytes mainly of
subcutaneous fat, so its level in the circulation is
directly correlated with subcutaneous fat (9,10). Leptin
decreases food intake and increases energy expenditure
through various mechanisms. Centrally, it acts mainly
on hypothalamic cells, inducing anorexigenic factors
and inhibiting orexigenic neuropeptides (11). It may
also regulate feeding behavior by affecting the cortex
and limbic areas (12). Peripherally, it has an autocrine or
paracrine-related role in lipid metabolism, inhibiting fatty
acids synthesis and stimulating lipolysis.
One of the several polymorphisms identified in this
gene is leptin rs7799039, a G-2548A leptin promoter
variant (located upstream of the LEP gene), which
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may have a role in the pathophysiology of obesity and,
consequently, MeS (13).		
The target of this study is to appraise the correlation
between vaspin rs2236242 and leptin rs7799039
polymorphic forms and the serum level of their
corresponding adipokines, vaspin and leptin, and to
evaluate the impact of these polymorphisms on the risk of
MeS in a sample of Egyptian women.
2. Materials and methods
2.1. Subjects
Women with and without MeS (n = 100 each) were
recruited in this case control study from Kasr Alaini
University Hospital in Cairo after having given their
informed consent. Ethical approval was obtained from
the Local Ethics Committee of the National Institute for
Research, Cairo, Egypt.
2.2. Anthropometric measures
The height, weight, hip circumference (HC), and waist
circumference (WC) were measured for each woman. BMI
was calculated by dividing weight in kg by squared height
in m2. WC was divided by HC to calculate waist/hip ratio
(WHR).
2.3. Diagnosis of metabolic syndrome
MeS was diagnosed according to the International Diabetes
Federation criteria, which include WC ≥ 80 cm (or BMI
≥ 30 kg/m2) in addition to any two of the following:
triglycerides (TG) ≥ 150 mg/dL, high density lipoprotein
cholesterol (HDL-C) ˂ 50 mg/dL, fasting plasma glucose
≥ 100 mg/dL, and blood pressure ≥ 130/85 mmHg, or
treatment of any of the above abnormalities (14).
2.4. Blood sampling and laboratory assays
After overnight fasting, blood samples were drawn from
consenting participants and were analyzed using standard
laboratory methods to determine plasma TG, glucose,
total cholesterol, HDL-C, and low density lipoprotein
cholesterol (LDL-C). Serum insulin concentration was
determined using the Immulite 1000 Automated Analyzer
(Diagnostic Products Corporation). The calculation of
insulin resistance (HOMA-IR) was done as fasting insulin
(mU/L) × fasting glucose (mg/dL) / 405 (15). A portion
of serum was kept frozen at –70 °C until the analysis for
serum vaspin and leptin levels was completed. The analysis
was determined using ELISA kits supplied by BioVender
GmbH-Laboratorni Medicina (Brno, Czech Republic)
and BioSource Europe S.A. (Nivelles, Belgium). Another
portion of blood was collected in EDTA-containing
vacutainer tubes and stored at –70 °C for genotyping
analysis.
2.5. Molecular analysis
2.5.1. DNA extraction
DNA extraction was done from EDTA-anticoagulated
whole blood using a DNA extraction kit provided
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by QIAGEN (Hilden, Germany) according to the
manufacturer’s instructions.
2.5.2. Genotyping of vaspin rs2236242 and leptin
rs7799039
Gene amplification was done by a tetra amplification
refractory mutation system polymerase chain reaction
(T-ARMS-PCR) for vaspin rs2236242 (16) and by a
conventional polymerase chain reaction (PCR) for leptin
rs7799039 (17) using the following primers: the primers
for vaspin rs2236242 were forward inner (T allele)
5’AAGACGCCGCTTCTGTGCACT3’, reverse inner
(A allele) 5’CACAGGGACCCAGGATAACTTGCT3’,
forward outer 5’GGAGGCAGACCAGGCACTAGAAA3’
and
reverse
outer
5’ACCATCTCTCTGGCT
TCAGGCTTC3’. The primers for leptin rs7799039 were
forward
5’TTTCCTGTAATTTCCCGTGAG3’
and
reverse 5’AAAGCAAAGACAGGCATAAAAA3’.
For vaspin rs2236242 amplification, an initial
denaturation of 5 min at 95 °C was followed by 30
amplification cycles each of 90 s with 30 s at 95 °C, 30 s at
62 °C, and 30 s at 72 °C, and then a final step for 10 min at
72 °C was performed. The amplification gives products of
174 bp for the T allele, 248 bp for the A allele, and 378 bp
for the control band. For leptin rs7799039 amplification,
an initial denaturation at 95 °C for 5 min was followed by
30 amplification cycles each of 3 min with 1 min at 94 °C,
1 min at 58.5 °C, and 1 min at 72 °C, followed by a final
extension for 7 min at 72 °C. The amplification products
(242 bp fragments) were digested at 37 °C for 60 min by
1.0 U/15 µL restriction enzyme, CofI Promega (Madison,
WI, USA), generating fragments of 61 bp and 181 bp when
the cleavage site was present. The PCR products of the
vaspin rs2236242 and the restriction fragment products
of the leptin rs7799039 were visualized by 2% agarose gel
electrophoresis stained with ethidium bromide.
2.6. Statistical analysis
SPSS 18.0 (SPSS Inc., Chicago, IL, USA) was used for
analysis. Continuous variables were expressed as mean
± standard deviation (SD) and categorical variables as
percentage and frequency. The frequency of different alleles
and genotypes in different groups were compared using the
chi-square test. The odds ratio (OR) and 95% confidence
intervals (CIs) of genetic risk in MeS were estimated by
logistic regression analysis. To compare means, we used
the independent Student t-test and ANOVA. To evaluate
the diagnostic value of serum vaspin and leptin and to
identify the cutoff values, receiver operating characteristics
analysis was used. P < 0.05 was regarded as significant.
3. Results
All observed subjects, both in the MeS group and the group
without metabolic syndrome, were in Hardy–Weinberg
equilibrium. All biochemical and anthropometric
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parameters of the participants in the study are presented in
Table 1. Serum vaspin levels showed significant increase in
cases of MeS (3.34 ± 0.52 ng/mL) when compared to nonMeS cases (1.87 ± 0.54 ng/mL), P < 0.001. Serum leptin
levels were also significantly higher in cases of MeS (36.7 ±
10.19 ng/mL) when compared to non-MeS cases (11.44 ±
5.88 ng/ml), P < 0.001.
Table 2 shows the cutoff values for both vaspin (≥2.80
ng/mL) and leptin (≥19.00 ng/mL) serum levels at which
the highest sensitivity and specificity were obtained to
distinguish the patients with MeS from those without MeS.
Table 3 shows no significant association between the
A allele of vaspin rs2236242 and MeS when compared
to the T allele, P = 0.08. The AT and AA genotypes also
showed no association with MeS when compared to the
TT genotype (wild type), with P = 0.08 for AT and P = 0.09
for the AA genotype.
On the contrary, the A allele of leptin rs7799039 is
associated with MeS when compared to the G allele,
P < 0.001. Only the AA genotype of leptin rs7799039
is associated with MeS and the risk of developing the
disease is 4 times that with the GG genotype, while the
GA genotype is not associated with the disease. For the
AA genotype, P < 0.001 and for the GA genotype, P = 0.94
(Table 3).

There was no significant difference in the serum
vaspin level in different polymorphic forms of vaspin
rs2236242, P = 0.33. On the contrary, serum leptin was
significantly different in different polymorphic forms of
leptin rs7799039, P = 0.011. Upon doing the post hoc test,
serum leptin levels were significantly higher in the AA
genotype (28.63 ± 13.45 ng/mL) when compared to the
GG genotype (19.70 ± 15.82 ng/mL), P = 0.008 (Table 4).
4. Discussion
Genetic predisposition and environmental factors have
been implicated in the development of MeS (18). Some
of the polymorphic genes known to be associated with
MeS are those encoding fat mass and obesity-associated
protein, cholesteryl ester transfer protein, apolipoprotein
E, and apolipoprotein C3 (19).
In our study, we investigated the possible association
between vaspin rs2236242 and leptin rs7799039 gene
polymorphism with the corresponding serum levels and
with the risk of developing MeS in a sample of Egyptian
women. To the best of our knowledge, this is the first time
such an association has been investigated in Egyptian
women.
Our findings showed significantly higher serum
levels of vaspin in patients with MeS when compared

Table 1. Characteristics of all participants in the study (values expressed as mean ± standard deviation).
MeS (n = 100)

Non-MeS (n = 100)

P

Age (years)

50.96 ± 6.38

45.44 ± 14.26

<0.001*

Height (cm)

157.00 ± 5.46

154.00 ± 6.89

0.07

Weight (kg)

93.54 ± 13.88

68.55 ± 22.38

<0.001*

BMI (kg/m2)

37.93 ± 5.24

28.60 ± 8.74

<0.001*

Waist circumference (cm)

112.38 ± 10.60

93.44 ± 19.80

<0.001*

Hip circumference (cm)

120.80 ±11.20

106.30 ± 15.90

<0.001*

Systolic blood pressure (mmHg)

135.58 ±14.92

126.67 ± 20.73

0.03*

Diastolic blood pressure (mmHg)

87.31 ± 13.21

68.55 ± 22.38

0.02*

Fasting plasma glucose (mg/dL)

96.91 ± 17.72

108.16 ± 22.35

0.46

Insulin

22.42 ± 5.82

16.44 ± 3.06

<0.001*

Insulin resistance

5.39 ± 1.87

4.37 ± 1.12

<0.001*

Triglyceride (mg/dL)

182.02 ± 112.81

139.65 ± 69.22

<0.001*

HDL-C (mg/dL)

38.51 ± 13.99

43.05 ± 13.33

0.02*

LDL-C (mg/dL)

122.20 ± 29.14

95.70 ± 30.14

<0.001*

Vaspin (ng/mL)

3.34 ± 0.52

1.87 ± 0.54

<0.001*

Leptin (ng/mL)

36.70 ±10.19

11.44 ± 5.88

<0.001*

a

b

High density lipoprotein cholesterol. b Low density lipoprotein cholesterol.
* Indicates significance at P < 0.05.
a
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Table 2. Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) for serum vaspin and leptin.
Serum vaspin

Serum leptin

Cutoff value (ng/mL)

≥2.80

≥19.00

Sensitivity (%)

84.00

97.00

Specificity (%)

92.00

90.00

PPV (%)

95.50

95.10

NPV (%)

74.20

93.80

to the control group. Choi et al. reported similar results
in a population of male patients with MeS (20). Some
reports have related the abnormalities in the circulating
levels of vaspin to individual components of MeS such
as BMI and insulin sensitivity. However, these results are
contradictory. Some researchers reported no significant
difference in serum vaspin levels between morbidly obese
and controls (21), while others reported significantly
higher serum vaspin in obese groups (22,23). Some
researchers found no significant difference in serum
vaspin levels between type 2 diabetes patients and controls
(22), whereas others found a positive correlation of serum
vaspin with insulin resistance (23).
Regarding the relationship between different
polymorphic forms of vaspin rs2236242 and serum vaspin

levels, this study showed no significant difference in the
vaspin level between different polymorphic forms of
vaspin rs2236242. In addition, no significant difference
in the allele and genotype frequency of vaspin rs2236242
polymorphism between the MeS and non-MeS groups
was detected. These results were contradictory to the
results obtained by Hashemi et al. (16), who reported that
genotypes carrying the A allele (TA and AA) diminished
the risk of MeS in comparison to the wild TT genotype
in all tested inheritance models. Kempf et al. (8) found
that the AA genotype of vaspin rs2236242 confers an
increased risk of type 2 diabetes when compared with the
TT genotype.
Regarding leptin, this study showed a significant
increase in the serum leptin level in the MeS group in
comparison to the non-MeS group. This is in line with
previous reports that correlated serum leptin levels with
MeS in different populations and supposed that it can
be useful as a diagnostic marker of the disease (24–27).
The highest sensitivity and specificity for the diagnosis
of metabolic syndrome were obtained at a cutoff value
of ≥19 ng/mL. The AA genotype of leptin rs7799039 was
associated with a higher serum leptin level when compared
to the wild GG genotype. The results of previous studies
were controversial. Some reports showed an association
of higher serum leptin levels with genotypes carrying the
A allele as shown by the results of this study (17,28,29).

Table 3. Association of the different polymorphic forms of vaspin rs2236242 and leptin rs7799039 with metabolic
syndrome (MeS).
Vaspin rs2236242

MeS (n = 100)

Non MeS (n = 100)

Odd ratio (OR) (95% CI)

P

T

127 (63.5%)

109 (54.5%)

A

73 (36.5%)

91 (45.5%)

0.69 (0.46 to 1.03)

0.08

TT

38 (38%)

25 (25%)

TA

51 (51 %)

59 (59%)

0.57 (–1.79 to 0.08)

0.08

AA

11 (11%)

16 (16%)

0.45 (–1.28 to 0.08)

0.09

G

86 (43%)

121 (60.5%)

A

114 (57%)

79 (39.5%)

2.03 (1.36 to 3.02)

<0.001*

GG

23 (23%)

32 (32%)

GA

40 (40%)

57 (57%)

0.97 (–0.68 to 0.67)

0.94

AA

37 (37%)

11 (11%)

4.66 (0.73 to 2.55)

<0.001*

Alleles

Genotypes

Leptin rs7799039
Alleles

Genotypes

* Indicates significance at P < 0.05.
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Table 4. Serum vaspin and leptin level (ng/mL) in different vaspin
rs2236242 and leptin rs7799039 genotypes (values expressed as
mean ± standard deviation).
N

Mean ± SD

F

P

1.132

0.33

4.585

0.011*

Vaspin rs2236242 genotypes
AA

21

2.748 ±1.00

AT

116

2.657 ± 0.96

TT

63

2.471 ± 0.75

Leptin rs7799039 genotypes
AA

48

28.63 ± 13.45

AG

98

24.24 ± 14.99

GG

54

19.70 ± 15.82

* Indicates significance at P < 0.05.

On the other hand, studies done on obese and nonobese
Greek women (30), obese Tunisian women (31), obese
Romanian subjects (32), healthy Spanish adolescents (33),
and Brazilian women (34) showed low serum leptin levels
in the AA genotype. Nevertheless, other studies reported
no significant difference in leptin levels in different leptin
rs7799039 genotypes (35,36).
The frequency of the A allele was significantly higher
in the MeS group in comparison to the control group, and
the leptin rs7799039 AA genotype was associated with
MeS. To our knowledge, there are no previous reports on
the association between leptin rs7799039 polymorphism
and metabolic syndrome, but there are reports on the

association of this gene polymorphism with obesity, which
is an important component of MeS. Riestret al. (33) and
Hinuy et al. (34) reported a significantly lower frequency of
the A allele in obese females. Mammes et al. (17) reported
this association only in obese males.
In summary, this study demonstrated that serum
vaspin and leptin levels are significantly higher in cases of
MeS and these levels can be used as diagnostic markers
of disease. The different polymorphic forms of vaspin
rs2236242 do not affect serum vaspin levels and are not
associated with MeS. The AA genotype of leptin rs7799039
is associated with higher serum leptin levels and metabolic
syndrome. Consequently, the results of previous research
are contradictory. This may be due to the interactions of
these polymorphisms with other polymorphisms of the
gene; the different ethnicities of the studied groups; the
sample sizes of the populations, which possibly affected the
statistical power; or the model used in statistical analysis.
It is recommended to test these results in a larger cohort
and in several populations in order to demonstrate the
validity of our findings. Environmental risk factors such
as diet or physical activity can also modify genetic effects,
so it is important that these be considered in subsequent
studies.
Recently, bioinformatics, such as multifactor
dimensionality reduction, has been used for the analysis of
gene × gene and gene × environment interactions and has
been emphasized as a new alternative for understanding
the etiology of common complex traits because the
above-mentioned interactions are difficult to detect
and characterize using traditional parametric statistical
methods.
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